Biofilm-producing organisms on implants complicate treatment, often requiring surgery beyond antibiotics.
Polymers, both natural and synthetic, are widely used in implants and drug delivery with tunable degradation and mechanical properties.
Guideline-Based Recommendations
Diagnosis
Recognize biofilm-related infections on implanted devices as difficult to cure with antibiotics alone.
Consider biomaterial type and degradation profile when evaluating infection risk.
Management
Surgical intervention is often necessary to eradicate mature biofilm infections on implants.
Use local antibiotic delivery systems such as collagen sponges loaded with gentamicin to reduce surgical site infections.
Monitoring & Follow-up
Monitor for signs of device-associated infection especially in permanent implants.
Assess wound healing and infection markers in patients with biomaterial implants.
Risks
Foreign body presence increases infection risk due to biofilm formation.
Naturally derived polymers may induce inflammation or carry disease transmission risk.
Non-biodegradable synthetic polymers may harbor persistent infection.
Patient & Prescribing Data
Patients with implanted biomedical devices at risk for device-associated infections
Local antibiotic delivery via biomaterial carriers (e.g., collagen sponges) can reduce infection rates; surgical removal often required for established biofilms.
Clinical Best Practices
Understand biomaterial composition and degradation properties to anticipate infection risks.
Incorporate biomaterial knowledge into infectious disease management plans for implant infections.
Utilize biomaterial-based local drug delivery systems to enhance antibiotic efficacy.
Collaborate with surgical teams for timely intervention in biofilm-associated device infections.
